Demand for Abbott’s portfolio of tests for Covid-19 surged in the fourth quarter as the company delivered more than 300 million such diagnostics in the fourth quarter alone and 400 million since the pandemic began in early 2020.
Demand for Abbott’s portfolio of tests for Covid-19 surged in the fourth quarter as the company delivered more than 300 million such diagnostics in the fourth quarter alone and 400 million since the pandemic began in early 2020.